{"id":"https://genegraph.clinicalgenome.org/r/e3c2582b-8444-4f76-8ed1-6b1c97ec62fbv1.0","type":"EvidenceStrengthAssertion","dc:description":"The IKZF3 gene encodes the transcription factor Aiolos. Aiolos is a member of the Ikaros family; as a transcription factor, it can bind DNA in essential regions to control hematopoiesis and cell functions of immune cells. Immunodeficiency 84 or immunodeficiency due to IKZF3 deficiency (MONDO:0030333), is characterized by profound defects in B cell differentiation, and severe hypogammaglobulinemia in patients. A total of two missense variants have been reported in 7 patients in 2 publications only (PMID: 34155405, 34694366). The two variants: p.G159R and p.N160S were found in autosomal dominant traits. Experimental evidence includes loss of the ability to form pericentromeric heterochromatin foci in the dimer IKZF1-IKZF3 affecting the transcriptional activity of genes under IKZF3 regulation. Additionally, the Aiolos knock in mice evaluating the homologous variants for p.G159R, and p.N160S showed that mice have profound defects in B cell development and low immunoglobulin levels (IgG, IgM and IgA), which is consistent with the phenotype seen in patients.  \nIn summary, there is moderate evidence to support this gene-disease relationship with only two variants identified in two publications.\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/e3c2582b-8444-4f76-8ed1-6b1c97ec62fb","GCISnapshot":"https://genegraph.clinicalgenome.org/r/e9112f2c-325e-4363-8a37-e7a8862bf55b","calculatedEvidenceStrength":"Moderate","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/e9112f2c-325e-4363-8a37-e7a8862bf55b_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10080","date":"2023-07-28T03:17:39.233Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/e9112f2c-325e-4363-8a37-e7a8862bf55b_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10080","date":"2023-03-21T17:00:00.000Z","role":"Approver"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e9112f2c-325e-4363-8a37-e7a8862bf55b_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8d8a8ffc-3697-467a-a8bb-1cfd549b58f3","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8d8a8ffc-3697-467a-a8bb-1cfd549b58f3_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Electrophoretic mobility shift assay (EMSA) confirmed that IKZF3 variant p.G159R loses the ability to bind DNA. ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/8d8a8ffc-3697-467a-a8bb-1cfd549b58f3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34155405","allele":{"id":"https://genegraph.clinicalgenome.org/r/282e028f-8cb7-4da2-89eb-d8b040a26358","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012481.5(IKZF3):c.475G>C (p.Gly159Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA399285046"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/5e3aeb41-b45d-4e5b-a6c9-fadcdfb77530","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5e3aeb41-b45d-4e5b-a6c9-fadcdfb77530_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"AIOLOS p.N160S variant loses the ability to form pericentromeric-heterochromatin (PC-HC) localization in the nucleus compared to the WT protein. ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/5e3aeb41-b45d-4e5b-a6c9-fadcdfb77530_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34694366","allele":{"id":"https://genegraph.clinicalgenome.org/r/64d99c07-2c93-4039-b2c2-8ed51dcb6795","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012481.5(IKZF3):c.479A>G (p.Asn160Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA399285006"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/e9112f2c-325e-4363-8a37-e7a8862bf55b_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/52155b5a-220e-401d-ae4f-e59ba60611e4_proband_segregation","type":"FamilyCosegregation","dc:description":"There is only three segregation for this family. The ClinGen SOP established a minimum of 4 segregation to include LOD scores. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34694366","rdfs:label":"Family A","estimatedLodScore":0.9,"family":{"id":"https://genegraph.clinicalgenome.org/r/52155b5a-220e-401d-ae4f-e59ba60611e4","type":"Family","rdfs:label":"Family A","ethnicity":{"id":"cg:UnknownEthnicity"},"member":{"id":"https://genegraph.clinicalgenome.org/r/a0f89ea0-b3e2-46d2-acb9-e1abebb21470","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34694366","rdfs:label":"Patient A.III.1","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":1,"allele":{"id":"https://genegraph.clinicalgenome.org/r/64d99c07-2c93-4039-b2c2-8ed51dcb6795"},"detectionMethod":"Whole Exome Sequencing in trio was performed for the index patient and parents. Sanger Sequencing confirmed the IKZF3 variant in the proband and father.","ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0005550","obo:HP_0020102","obo:HP_0002721","obo:HP_0002205","obo:HP_0004313","obo:HP_0001508"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/5e3aeb41-b45d-4e5b-a6c9-fadcdfb77530_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":4,"phenotypes":["obo:HP_0002721","obo:HP_0020102","obo:HP_0005550"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/a0f89ea0-b3e2-46d2-acb9-e1abebb21470"}},{"id":"https://genegraph.clinicalgenome.org/r/21d09b1d-b9a8-4666-a6c1-451fb66a5a88_proband_segregation","type":"FamilyCosegregation","dc:description":"There is only 2 segregations for this family.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34155405","rdfs:label":"Family A","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/21d09b1d-b9a8-4666-a6c1-451fb66a5a88","type":"Family","rdfs:label":"Family A","ethnicity":{"id":"cg:UnknownEthnicity"},"member":{"id":"https://genegraph.clinicalgenome.org/r/5e2f1d37-f38e-4801-9926-8fdbf7b06573","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34155405","rdfs:label":"Patient P1","ageType":"AgeAtDeath","ageUnit":"Years","ageValue":42,"allele":{"id":"https://genegraph.clinicalgenome.org/r/282e028f-8cb7-4da2-89eb-d8b040a26358"},"detectionMethod":"IKZF3 was identified using Whole exome sequencing; the familiar segregation was confirmed by Sanger sequencing.","ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001744","obo:HP_0012539","obo:HP_0005425","obo:HP_0004313","obo:HP_0031693","obo:HP_0010976","obo:HP_0001876"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/8d8a8ffc-3697-467a-a8bb-1cfd549b58f3_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0010976","obo:HP_0031693"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/5e2f1d37-f38e-4801-9926-8fdbf7b06573"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/e9112f2c-325e-4363-8a37-e7a8862bf55b_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e9112f2c-325e-4363-8a37-e7a8862bf55b_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/26c73602-65a9-4d99-b43f-7287282b8336","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6919a8cf-eedc-46a6-a167-231688293084","type":"Finding","dc:description":"The B cell development was evaluated in Ikzf3 G158R knock-in mutant mice. Profound B cell developmental defects: blockade at the stages of pre-pro-B cells to pro-B cells and pre-B cells accompanied by a significant decrease in pre-B cells and later stages of B cells in the BM and notable decreases in all B cell subsets in the spleen were observed in the homozygous Ikzf3G158R/G158R mice, and a milder effect was observed in the heterozygous WT/G158R.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34155405","rdfs:label":"AIOLOS p.G158R mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/5f4f8e1e-3aec-43b8-9f59-2f1b98de31f8","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cf218cb9-6ea5-4705-8583-736d7312d3ac","type":"Finding","dc:description":"The B cell development was evaluated in Ikzf3 G159S knock-in mutant mice. Mature follicular B cells were significantly decreased in both hetero and homozygous mice. Serum IgG, IgA and IgM were also significantly decreased.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34694366","rdfs:label":"AIOLOS p.N159S mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/e9112f2c-325e-4363-8a37-e7a8862bf55b_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a785dd04-a8d0-43f3-80b5-a994b9f6d095","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e9cb658b-6867-4b58-9850-2840b62e7e99","type":"FunctionalAlteration","dc:description":"Analysis of B cell levels in peripheral blood demonstrated undetectable levels of B cells. Further studies in bone marrow showed low proportions of B cell lineage-committed progenitors and immature B cell fractions. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34155405","rdfs:label":"B cell differentiation"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/49e94b1f-a0be-4980-88ba-a46f910594cf","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f0aaa081-c85f-4c30-9239-df7a893b092f","type":"FunctionalAlteration","dc:description":"The four patients carrying the AILOS p.N160S variant showed profound defects in B cell proliferation upon stimulation with anti-IgM, CD40L, and IL-4. In addition to that, the plasmablast differentiation was completely abolished in the patientÂ´s cells. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34694366","rdfs:label":"B cell proliferation and differentiation"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/e9112f2c-325e-4363-8a37-e7a8862bf55b_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/502d184d-ecdf-443a-8ec2-62629d252f15","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7fcc5379-0690-4de5-bc50-1bb310915def","type":"Finding","dc:description":"IKZF1 and IKZF3 are part of the transcription factor family IKAROS. They have two dimerization domains, and it is well-proven in mice models and humans that IKZF1 and IKZF3 products can interact to form heterodimers and activate the transcription of essential genes in hematopoiesis. The IKZF3 (AIOLOS) variant p.G159R can form heterodimers with WT IKZF1 (IKAROS) protein; however, the dimer loses the ability to form pericentromeric heterochromatin foci.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34155405","rdfs:label":"IKZF3-IKZF1 dimerization","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Moderate","sequence":6661,"specifiedBy":"GeneValidityCriteria9","strengthScore":7,"subject":{"id":"https://genegraph.clinicalgenome.org/r/yKQFGORk96s","type":"GeneValidityProposition","disease":"obo:MONDO_0030333","gene":"hgnc:13178","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_e9112f2c-325e-4363-8a37-e7a8862bf55b-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}